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ABSTRACT
BACKGROUND: Although superior vena cava (SVC) stenosis may be a life-threatening complication of
haemodialysis (HD) catheters, its prevalence and risk factors in HD patients are unknown. Our aim was
to assess the prevalence and risk factors for SVC stenosis in HD patients with a tunnelled cuffed catheter
(TCC) and to describe its clinical presentation. METHODS: In this single-centre, retrospective cohort study,
all in-centre chronic HD patients carrying a TCC (1 January 2008-31 December 2012) were included (n =
 117 patients, 214 TCC, 80 911 catheter-days). SVC stenosis was defined as a diameter reduction >50%
on phlebography or computed tomography. Imaging was triggered by clinical SVC stenosis syndrome
or vascular access (VA)-related concerns. We recorded demographics, conditions potentially influencing
catheter permeability (medications, carriage of thoracic devices), number of TCCs, total duration of TCC
carriage, previous arteriovenous VA and last (in use at time of stenosis detection) TCC details (location,
diameter and length). VAs created while a TCC was still used were also recorded. RESULTS: An SVC
stenosis was found in 11 patients (9.4%, 0.14/1000 catheter-days), which represents almost one-quarter
of patients undergoing imaging, whatever the cause (11/45). Only two presented with clinically obvious
SVC stenosis. The number of TCCs per patient was 2.64 ± 1.8 in the SVC stenosis group versus 1.75 ±
 0.94 in the negative group (P = 0.13). On multivariate analysis (Poisson), diabetes {incidence rate ratio
[IRR] 4.63 [confidence interval (CI) 1....
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A B S T R A C T
Background. Although superior vena cava (SVC) stenosis may
be a life-threatening complication of haemodialysis (HD) cathe-
ters, its prevalence and risk factors in HD patients are unknown.
Our aim was to assess the prevalence and risk factors for SVC
stenosis in HD patients with a tunnelled cuffed catheter (TCC)
and to describe its clinical presentation.
Methods. In this single-centre, retrospective cohort study, all
in-centre chronic HD patients carrying a TCC (1 January 2008–
31 December 2012) were included (n¼ 117 patients, 214 TCC,
80 911 catheter-days). SVC stenosis was defined as a diameter
reduction >50% on phlebography or computed tomography.
Imaging was triggered by clinical SVC stenosis syndrome or
vascular access (VA)-related concerns. We recorded demo-
graphics, conditions potentially influencing catheter permeabil-
ity (medications, carriage of thoracic devices), number of TCCs,
total duration of TCC carriage, previous arteriovenous VA and
last (in use at time of stenosis detection) TCC details (location,
diameter and length). VAs created while a TCC was still used
were also recorded.
Results. An SVC stenosis was found in 11 patients (9.4%, 0.14/
1000 catheter-days), which represents almost one-quarter of
patients undergoing imaging, whatever the cause (11/45). Only
two presented with clinically obvious SVC stenosis. The num-
ber of TCCs per patient was 2.64 6 1.8 in the SVC stenosis
group versus 1.75 6 0.94 in the negative group (P¼ 0.13). On
multivariate analysis (Poisson), diabetes {incidence rate ratio
[IRR] 4.63 [confidence interval (CI) 1.2–17.8]; P¼ 0.02} and to-
tal duration of TCC carriage [IRR 1.47 (CI 1.2–1.8) per year;
P¼ 0.001] were associated with SVC stenosis, whereas age had
a slightly protective effect [IRR 0.96 (CI 0.91–1.01); P¼ 0.01].
Limitations are the retrospective design, detection and survivor
bias.
Conclusion. SVC stenosis is not a rare condition, is mostly
asymptomatic in the absence of a peripheral VA, is strongly as-
sociated with diabetes and is promoted by long TCC carriage.
Age is slightly protective.
Keywords: catheters, central vein stenosis, haemodialysis, su-
perior vena cava stenosis
I N T R O D U C T I O N
Central vein stenosis (CVS) [i.e. subclavian/innominate veins,
superior vena cava (SVC)] is a significant cause of vascular ac-
cess (VA) failure and causes significant morbidity in haemo-
dialysis (HD) patients. Although the association of CVS
with previous central venous devices has been known for deca-
des [1, 2], its actual prevalence remains unknown and is likely
to be underestimated since published data report on symptom-
atic patients [3].
The pathogenesis of CVS remains unclear. A plausible
mechanism is the trauma to the venous endothelium caused by
the catheter. This intimal injury may induce an early (<14 days)
inflammatory response within the vessel wall and the onset of a
non-organizing thrombus [4]. Many other factors, such as pos-
tural and respiratory movements and high turbulent flow asso-
ciated with HD, may contribute to increased shear stress,
stimulating platelet aggregation, thrombus organization and in-
timal hyperplasia with subsequent thickening of the venous
wall, leading eventually to intravascular thrombosis with ve-
nous occlusion [3].
Several risk factors for CVS have been postulated, i.e. the
number of total central venous catheters and the duration of
catheter carriage [1, 5, 6], subclavian [1, 2, 7] and/or left-sided
location [8], history of catheter-related infections [9], larger
catheter diameter and the presence of wires of intracardiac devi-
ces [10]. However, CVS has been reported even in HD
patients without any history of previous central vein catheteri-
zation [5, 11], suggesting that the high blood flow of a func-
tional arteriovenous fistula (AVF) or arteriovenous graft
(AVG) may play a causative role [11].
The SVC syndrome results from stenosis or occlusion of the
SVC or both innominate veins. The classical clinical presenta-
tion includes swelling of the upper extremities, face and neck.
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Without treatment, SVC syndrome may lead to life-threatening
complications, such as airway compression due to oedema,
downhill oesophageal varices, increased intracranial pressure
and pleural effusion. However, the actual prevalence and risk
factors of SVC stenosis are unknown.
The purpose of this study is thus to assess the prevalence of
SVC stenosis, to depict its clinical presentation and to define
risk factors for SVC stenosis in a population of prevalent and
incident chronic HD patients with a history of carriage of a per-
manent HD catheter between 2008 and 2012.
M A T E R I A L S A N D M E T H O D S
Patients
In this observational retrospective study we included all in-
centre chronic HD patients, both prevalent and incident, carry-
ing a tunnelled cuffed catheter (TCC), either internal jugular or
subclavian, between 1 January 2008 and 31 December 2012, in
a tertiary care hospital (Cliniques universitaires Saint-Luc,
Brussels, Belgium). For each patient, demographic and medical
history data, as well as medications potentially influencing cath-
eter permeability such as anticoagulants and/or antiplatelet
agents (coumarin and heparin derivatives, aspirin, clopidogrel),
were extracted from the electronic medical records. We also
recorded the conditions that might be considered as risk factors
for an SVC stenosis, such as carriage of a venous port,
pacemaker or defibrillator, and all episodes of catheter-related
bacteraemia. Time spent on chronic HD, the number of previ-
ous AVFs or AVGs (VA), the total number of TCCs and char-
acteristics of the last TCC carried during 2012—or the one in
use when SVC stenosis was diagnosed [location (right or left,
internal jugular or subclavian), brand, diameter, length and du-
ration of carriage]—were also recorded. We further recorded
the presence of a VA created while a TCC was still in use.
We calculated the number of days the TCC(s) stayed in place
in every patient until the diagnosis of SVC stenosis, death, kid-
ney transplantation, transfer to another HD centre, TCC re-
moval after use of a mature AVF or until 31 December 2012,
whichever came first. Femoral TCCs and non-tunnelled, tem-
porary catheters were excluded. All patients were dialysed
three times a week (4 h in> 90% of cases) using hollow-fibre
high-flux or superflux polysulphone dialysers (Fresenius, Bad
Homburg, Germany).
The study protocol was performed in accordance with the
Helsinki Declaration and was approved by the Ethics
Committee of the Université catholique de Louvain.
Endpoint and definitions
The endpoint of this study was SVC stenosis or thrombosis.
This diagnosis was made in two situations:
(i) Clinically evident SVC stenosis: swelling of the face,
neck and/or upper part of the chest, extending in some
cases to the proximal part of the upper limbs. The SVC
stenosis then had to be confirmed by a venography
showing significant stenosis of the SVC (see below).
(ii) SVC stenosis diagnosed radiologically, without the typi-
cal clinical signs described above, in the context of any
clinical situation (i.e. VA-related concerns; isolated arm,
breast or face oedema) leading to the prescription of a
venography or a standard chest computed tomography
(CT) with contrast. Catheter malfunction was defined as
a persistent inability to achieve a blood flow >250 mL/
min (despite postural changes of the patient, additional
flushing and use of urokinase as a catheter lock for three
consecutive HD sessions). In patients carrying a recently
created AVF while still using a TCC, indications of a ve-
nography included arm oedema, impaired AVF matura-
tion, hand ischaemia or decreased thrill.
Criteria defining a significant stenosis of the SVC were set
according to those proposed by Lumsden et al. [12] in 1997,
currently widely used in the field of veno-occlusive diseases;
that is, a stenosis is significant when the diameter reduction
is>50% with or without upstream collaterals. Stenoses of supe-
rior central veins other than the SVC were not recorded as SVC
stenosis, even in case of clinical SVC syndrome (i.e. bilateral
subclavian or innominate veins occlusion). Diagnostic venogra-
phy was performed over both lumens of the TCC (in case of
TCC dysfunction) or by direct VA puncture in patients with
VA-related concerns. When appropriate, percutaneous balloon
angioplasty of the SVC was performed after TCC removal over
a guidewire and local administration of 3000 U of heparin. The
balloon size was determined according to the angiographic
findings (12–18 mm); after the insertion of the guide wire, bal-
loons were inflated at 8–12 atm for 60 s. A technical success was
defined by a residual stenosis<30%. A bare self-expanding niti-
nol stent (Sinus-XL stent; Optimed, Ettlingen, Germany) was
placed in case of elastic vein recoil leading to a significant resid-
ual stenosis after angioplasty, or for relapsing stenosis.
Restenosis was defined as a previously treated segment with an
angiographic>50% stenosis. All venographies were performed
by the same interventional radiologist (F.H.), except in Patient
4 (whose images were reviewed by F.H.).
All venographies and chest CTs performed in included
patients during follow-up, whatever the indication, were
reviewed retrospectively. To retrieve possibly missed cases of
SVC stenosis, we screened the medical imaging database, look-
ing after the billing codes associated with venous angioplasty
and stenting procedures.
Statistical analysis
For each patient, the total time on HD was retrieved from
the charts. The incidence rate of SVC stenosis was calculated as
a person-time rate with the numerator equal to the number of
observed episodes of SVC stenosis over the period of interest
and was standardized to 1000 catheter-days per patient. The in-
cidence rate per categorical explanatory variable was corrected
for the risk period (catheter-days per patient). Univariate analy-
sis was performed using chi-square for categorical variables and
t-test for continuous variables. Incidence rate ratios (IRRs) were
calculated using Poisson regression, adjusting for variables
showing a significant association with endpoint in univariate
analysis. Statistical significance level was set at P< 0.05.
Given that the duration of the last TCC was associated with
SVC stenosis in the group with two or more TCCs (t-test 2.26;
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P¼ 0.043), but not in the group with only one TCC, we created a
binary variable (0/1) to flag patients who had more than one TCC.
R E S U L T S
A total of 117 patients (59 males), 214 TCC and 80 911
catheter-days, were included (i.e. 100% of the candidate patients
and catheter-days). Overall, patients were 65.9 6 15 years of age
and 43.5% were diabetic. TCCs were carried for 697 (range 44–
4246) days. The median number of TCCs per patient was 1.8
(range 1–7). All TCCs were routinely locked with heparin
5000 IU/mL. Table 1 shows the main demographic characteris-
tics of the included patients as well as those of the SVC stenosis
group compared with the SVC stenosis negative group, without
adjustments. The use of antiplatelet agents, oral anticoagulants
and thoracic venous devices was not significantly different be-
tween groups (data not shown).
During the study period, 75 patients started chronic HD.
Thirty peripheral VAs (29 AVFs and 1 AVG) were created
while a TCC was still used for HD (11 AVFs were ipsilateral to
the TCC), and conversely six patients had a maturating AVF
(three ipsilateral to the TCC) when a TCC was placed. Eight
venographies were performed because of AVF- or AVG-related
concerns, including arm oedema (n¼ 1), increased venous
pressures (n¼ 4), impaired access maturation (n¼ 2) and pro-
longed haemostasis (n¼ 1). Only two showed CVS (one at the
subclavian vein level in the patient with arm oedema and one at
the innominate vein level in an AVF with increased venous
pressures); the others documented a peripheral vein stenosis.
Two patients, one of whom was carrying a left AVF ipsilateral
to the TCC, had AVF failure due to thrombosis.
SVC stenosis
During follow-up, 45/117 patients underwent venography in
the setting of one of the clinical situations detailed in the
‘Materials and methods’ section. Eleven patients had an SVC ste-
nosis (9.4%, 0.14 case/1000 catheter-days). Only two of them
(Patients 3 and 4) presented with clinically evident SVC syndrome
(Table 2). None of them had concomitant bilateral occlusion of in-
nominate veins. Interestingly, both patients had been diagnosed
with a ‘food allergy’ in the emergency room 2 days before.
One patient (Patient 5) suffered from right arm oedema ipsi-
lateral to the TCC, in the absence of a maturating AVF. In six
patients the venography was performed because of catheter
malfunction. In the remaining two patients, SVC stenosis was
found on chest CT scans performed for a reason unrelated to
the VA (thoracic pain and suspected pneumonia in Patients 1
and 9, respectively) and subsequently confirmed by venography
in both patients. Only one patient (Patient 9) suffered from ac-
tive neoplasia. Four patients also had a stenosis at the right in-
nominate vein (Patients 5 and 6) or at the junction of both
innominate veins (Patients 4 and 8) concomitant to a severe
SVC stenosis. In Patients 4 and 7, the SVC was completely oc-
cluded. A thrombus within the SVC stenosis was documented
in Patients 1, 4, 5 and 9. In only one patient (Patient 10), an
AVF was created while a TCC was still in use (both the AVF
and TCC were right-sided). In this patient, the AVF matured
without problems and the venography was performed because
of catheter malfunction.
The TCC was eventually removed in all but one case
(Patient 9, suffering from advanced neoplasia). In both patients
with an SVC syndrome, a thrombolytic treatment by local
(Patient 4) or systemic (Patient 3) urokinase was unsuccessful;
the TCC was removed over guidewire and replaced after SVC
angioplasty. In Patients 7 and 11, a stent (18  60 mm and
22  60 mm, respectively) was placed after SVC angioplasty:
during the study, SVC stenosis recurred in two patients,
Patients 3 and 11, 2 and 4 months after SVC angioplasty, re-
spectively. The clinical presentation was catheter malfunction
in Patient 11. Patient 3 was asymptomatic when SVC stenosis
relapsed. One month after relapse she received kidney trans-
plantation. Patient 11 died 2 months after SVC stenosis relapse.
Patients in the SVC stenosis group were younger and more
likely to be diabetic (Table 1), whereas the number of previous
AVFs and characteristics of the last TCC did not differ between
groups. Of note, only 3 of 11 TCCs in the SVC stenosis group
were placed on the left side (Patients 5, 7 and 8) and 11/11 were
internal jugular TCCs. Also of note, 5 of 11 patients in the SVC
stenosis group carried only one TCC.
The number of TCCs and catheter-days per patient were
higher in the SVC stenosis group compared with the negative
group, but this did not reach statistical significance (2.64 6 1.8
versus 1.75 6 0.94, P¼ 0.13 and 1302 6 122 versus 634 6 691,
P¼ 0.08, respectively). The duration of total TCC carriage in
the SVC stenosis group was strongly driven by Patient 7
(>4000 catheter-days).
Univariate analysis
Only diabetes {IRR 5.7 [confidence interval (CI) 1.2–26.2],
P¼ 0.03}, age [IRR 0.96 (CI 0.91–1.01), P¼ 0.01] and duration
of last catheter carriage [IRR 0.996 (CI 0.993–0.999), P¼ 0.03]
were significantly associated with SVC stenosis in univariate
analysis. Body mass index, HD vintage, number of previous
AVFs/AVGs, number of TCCs and characteristics of the last
TCC [diameter, length, location (either side or vein)] were not
significantly associated with IRR.
Multivariate analysis
In the multivariate Poisson regression, diabetes [IRR 4.9 (CI
1.03–23.6), P¼ 0.04] and the duration of last catheter carriage
[IRR 0.99 (CI 0.994–1.0002), P¼ 0.07] were independent predic-
tors of SVC stenosis (Table 3). After adjustment for the number
of previous catheters, the impact of duration of the last catheter
carriage was non-significant. After excluding the duration of last
catheter carriage, diabetes and the total duration of TCC carriage
remained significantly associated with SVC stenosis [IRR 4.63
(CI 1.2–17.8), P¼ 0.02 and 1.47 (CI 1.22–1.76), P¼ 0.001, re-
spectively]. Age was slightly protective [IRR 0.96 (CI 0.91–1.01),
P¼ 0.01]. Using a Fisher test, the age category (considered as
20-year increments) remained borderline significant (P¼ 0.06).
D I S C U S S I O N
Although SVC stenosis may be a life-threatening condition in
HD patients with a TCC, its current prevalence and risk factors
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are unknown. To our knowledge, this is the first long-term
(5 years) report documenting a prevalence of SVC stenosis in
in-centre HD patients carrying a tunnelled central venous cath-
eter. Additionally, this study provides a description of the clini-
cal presentation and management of SVC stenosis in HD
patients. The presumed prevalence of SVC stenosis was 0.14
case/1000 catheter-days. This corresponds to 1.8 episodes of
SVC stenosis per year in a centre with 100 HD patients, one-
third of whom carry a TCC, thus it is not very rare. Moreover,
the prevalence might be even higher since only symptomatic
patients (45/117) underwent imaging. Furthermore, an SVC
stenosis was found in almost one-quarter of the patients under-
going a venography, whatever the trigger (11/45). A PubMed
search using the keywords ‘superior vena cava stenosis and he-
modialysis’ ‘superior vena cava stenosis and dialysis catheter’,
and ‘superior vena cava stenosis and vascular access’ yielded 46
articles. All but one [13] were case reports and case series,
reporting a total of 91 cases of SVC stenosis in HD patients.
Most published cases (n¼ 35) describe a classical SVC syn-
drome, followed by catheter malfunction (n¼ 14) and
Table 1. Patients demographics and catheter-related factors in the SVC stenosis group compared with the SVC stenosis–negative group
Total SVC stenosisgroup SVC stenosis–negative group P-
value
(n¼ 117) (n¼ 11) Venography (n¼ 34) No venography (n¼ 72) All (n¼ 106)
Age (years), mean (SD) 66 (11.9) 57.9 (11) 68.4 (6.8) 66.2 (12.3) 66.8 (11.8) 0.02
Diabetes, n (%) 51 (43.6) 9 (81.8) 11 (30.5) 36 (51.4) 42 (39.6) 0.007
BMI (kg/m2), mean (SD) 24.9 (4.4) 26.5 (4.7) 27.1 (5.1) 24.2 (3.9) 24.7 (4.3) 0.2
HD vintage (days)
Mean (SD) 1202 (953) 1503 (1303) 1250 (693) 1131 (937) 1176 (1279) 0.3
Median (range) 720 (60–6126) 1640 (115–4246) 1037 (270–3780) 641 (60–6126) 709 (60–6126)
Number of AVF per patient 0.2
Mean (SD) 0.85 (0.67) 1.1 (0.9) 1.2 (0.5) 0.8 (0.7) 0.8 (0.65)
Median (range) 1 (0–3) 1 (1–3) 1 (0–3) 1 (0–3) 1 (0–3)
Total number of TCCs per patient 0.1
Mean (SD) 1.84 (1.02) 2.64 (1.8) 2.8 (1.7) 1.6 (0.7) 1.75 (0.94)
Median (range) 1 (1–7) 2 (1–7) 2 (1–6) (1–5) 1 (1–6)
Catheter-days per patient 0.08
Mean (SD) 677 (548) 1302 (1218) 1044 (813) 525 (391) 634 (691)
Median (range) 375 (44–4246) 1350 (44–4246) 543 (218–3780) 343 (50–2338) 371 (50–3780)
Characteristics of last TCC
Duration (days) 0.2
Mean (SD) 391 (297) 250 (192) 592 (455) 360 (260) 400 (299)
Median (range) 240 (11–3780) 240 (21–1035) 309 (30–3780) 225 (11–2180) 241 (11–3780)
Side, n (%)
Right 96 (82.1) 8 (72.7) 33 (91.7) 55 (78.5) 88 (83) 0.5
Left 21 (17.9) 3 (27.3) 3 (8.3) 15 (21.4) 18 (17)
Vein, n (%)
Jugular 110 (94) 11 (100) 32 (88.9) 67 (95.7) 99 (93.4) 0.4
Subclavian 7 (6) 0 4 (11.1) 3 (4.3) 7 (6.6)
Brand, n (%)
Hemosplit 85 (72.6) 7 (63.6) 25 (70) 53 (75.7) 78 (73.6) 0.8
DuraFlow 11 (9.4) 1 (9.1) 2 (5) 7 (10) 9 (8.5)
Arrow 2 (2.6) 1 (9.1) 0 0 2 (1.9)
Other 8 (6.8) 1 (9.1) 5 (15) 2 (2.9) 7 (6.6)
Unknown 10 (8.5) 1 (9.1) 4 (11) 15 (21.4) 19 (17.9)
Length (cm), n (%) 0.8
19 27 (23.1) 3 (36.4) 5 (15) 18 (25.7) 23 (21.7)
23 43 (36.8) 1 (27.3) 14 (40) 28 (40) 42 (39.6)
24 6 (5.1) 0 0 6 (8.6) 6 (5.7)
26 2 (1.7) 0 2 (5) 0 2 (1.9)
27 13 (11.1) 2 (18.2) 2 (5) 9 (12.9) 11 (10.4)
28 10 (1.7) 0 0 2 (2.9) 2 (1.9)
Unknown 21 (17.5) 2 (18.2) 7 (20) 12 (17.1) 19 (17.9)
Diameter (F), n (%) 0.4
13 1 (0.85) 1 (9.1) 0 0 0
13.5 1 (0.85) 0 0 1 (1.4) 1 (0.94)
14 1 (0.85) 0 0 1 (1.4) 1 (0.94)
14.5 30 (25.6) 5 (45.5) 6 (17) 19 (27.1) 25 (23.6)
15 1 (0.85) 0 0 1 (1.4) 1 (0.94)
15.5 5 (4.3) 1 (9.1) 2 (5.5) 2 (2.9) 4 (3.8)
16 2 (1.7) 0 0 2 (2.9) 2 (1.9)
Unknown 76 (65) 4 (36.4) 22 (61) 50 (71.4) 72 (67.9)
BMI, body mass index. Hemosplit: Bard Access Systems, C.R. Bard, Murray Hill, NJ, USA; DuraFlow: AngioDynamics, Latham, NY, USA; Arrow: Teleflex, Athlone, Westmeath,
Ireland.
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‘downhill’ oesophageal varices (n¼ 11). In seven cases, clinical
presentation included other symptoms (chylothorax and chylo-
pericardium, haemoptysis, obstructive sleep apnoea, stridor, in-
tracranial hypertension and recurrent right-sided transudative
pleural effusion) [14–16].
In our study, a classical SVC syndrome was present in only
two patients. Indeed, in most cases SVC stenosis was diagnosed
in the context of catheter malfunction. Similarly, in a very small
prospective study focusing on SVC and including 20 patients
with a permanent jugular catheter who underwent systematic
transesophageal echocardiography, 5 of 6 patients with an SVC
thrombosis presented with reduced catheter blood flow during
HD [13]. Although small and cross-sectional, this is the only
published study focusing on SVC stenosis in HD patients. Jean
et al. [17] showed that only 50% of the 24 patients with a docu-
mented CVS in a systematic cavographic study (n¼ 51, includ-
ing 7 AVFs, 2 AVGs, 2 Thomas shunts and 40 TCCs) were
symptomatic, but unlike in the study by Grote et al. [13] and in
our study, symptoms/signs included limb oedema, collateral
circulation and hepatalgia. This difference in clinical presenta-
tion may be explained by the fact that in the study by Jean et al.
[17], 9 of 12 symptomatic patients were using an AVF/AVG at
the time of the cavography (versus no asymptomatic patient).
Indeed, increased blood flow through the AVF can lead to ve-
nous congestion [18]. Similarly, in 55 cases of CVS among 133
prevalent HD patients undergoing a venography due to a prob-
lematic AVF, arm oedema was a frequent clinical manifestation
of CVS (10 CVSs out of 13 cases of arm oedema) and 8 patients
had a clinical classical SVC syndrome among 13 carrying an
SVC stenosis [5]. However, Renaud et al. [11] found that
among 103 patients carrying an AVF and a high-grade CVS,
only 50 were symptomatic (severe arm oedema) and the AVF-
related problems in the other 53 patients were all due to
peripheral vein stenoses [11]. In our study, the fact that only
three patients with SVC stenosis were symptomatic strongly
suggests that, just like stenosis of other central veins, it does not
necessarily correlate with clinical symptoms, especially in the
absence of an AVF or AVG, and that a number of SVC stenoses
are incidentally detected. However, it is important to emphasize
that, even if clinically silent in most cases, SVC stenosis can lead
to dramatic complications, such as massive bleeding by ‘down-
hill’ oesophageal varices [19, 20] or torrential haemoptysis [16],
chylopericardial tamponade [15] and death [5].
Our study demonstrates, as already shown for CVS [2, 5,
21], that a longer duration of catheterization is associated with
the development of SVC stenosis. In our study, the number of
previous TCCs was higher in patients with SVC stenosis, but
without reaching statistical significance. This may be explained
by the small number of positive cases and also the fact that tem-
porary catheters were not included.
Unlike McRae et al. [5], we found that diabetes was strongly
associated with SVC stenosis. In this study there was no differ-
ence in the prevalence of diabetes in patients carrying a CVS
(49%) versus those without (43%). However, only patients with
a problematic AVF were included, which could have caused an
overrepresentation of diabetes in both groups [5]. Intimal hy-
perplasia—currently considered as one of the culprit lesions in
failing AVFs [22]—is caused by the accumulation of
myofibroblast-like cells in the venous intima [23] and seems to
be associated with endothelial dysfunction due to turbulent
flow [22]. Some [24] but not all [25] studies found a significant
association of histologic intimal hyperplasia with diabetes in
patients carrying an AVF. To our knowledge, no study has in-
vestigated this potential association in patients carrying cathe-
ters. Diabetes has been identified as a predictor of AVF loss
[26]. Admittedly, it is unclear if this may be extrapolated to
patients carrying central catheters. Nonetheless, it is tempting
to speculate that the endothelial dysfunction and the pro-
inflammatory status due to diabetes itself could exacerbate the
biological response to the mechanical injury caused by the cath-
eter and abnormal flow conditions, increasing the expression of
pro-coagulant and pro-inflammatory mediators and predispos-
ing to intimal hyperplasia and vessel stenosis.
We found that age has a slightly protective effect on SVC ste-
nosis. A plausible though purely speculative explanation may



















1 80 35.6 Yes No 248 1 Asymptomatic No No No No
2 50 27.8 Yes No 2040 1 TCC malfunction No No PTA Yes
3 34 22.3 Yes No 252 1 SVC syndrome No Yes Local lysis/PTA Yes
4 37 19.3 Yes No 1648 4 SVC syndrome No No Systemic lysis / PTA Yes
5 55 18.4 No No 2871 2 Arm oedema No No No Yes
6 53 33.4 Yes No 2010 3 TCC malfunction No No PTA Yes
7 69 20.3 No No 4246 7 TCC malfunction No No PTA/stent Yes
8 69 30.1 Yes PM 1640 6 TCC malfunction No No PTA Yes
9 60 26.4 Yes PAC 118 1 Asymptomatic No NA No No
10 65 30.8 Yes No 115 1 TCC malfunction Yes No No Yes
11 65 26.9 Yes No 1350 2 TCC malfunction No Yes PTA/stent Yes
BMI, body mass index; NA, not applicable; PAC, venous port; PM, pacemaker; PTA, percutaneous angioplasty.
Table 3. Multivariate analysis (Poisson regression)
IRR CI P-value
Diabetes 4.63 1.2–17.8 0.02
Total catheter-days 1.47 1.22–1.76 0.001
Age 0.96 0.91–1.01 0.01
Total number of TCCs 1.09 0.76–1.57 0.6
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be the age-related modulation of the immune response [27].
However, we cannot exclude a detection bias, due to the fact
that in elderly patients one may be less prone to perform cum-
bersome imaging studies and a lower blood flow may be
tolerated.
The main limitation of this study is its retrospective design.
Second, because the study included both incident and prevalent
patients, there may be a survivor bias. Third, there is a detection
bias because only patients carrying a TCC during the study pe-
riod were included (patients using a TCC before the study and
carrying an AVF during the study were not). Furthermore, CVS
has also been reported in patients carrying a functional periph-
eral VA who do not have a history of central vein catheteriza-
tion (5–63% in two series including 51 and 103 documented
CVSs, respectively [5, 11]). Additionally, unlike the study by
Jean et al. [17] in which all included patients underwent a sys-
tematic cavography, imaging was performed only in symptom-
atic patients. Fourth, some data were missing concerning the
characteristics of the last catheter, which could explain the ab-
sence of an association of SVC stenosis with some catheter
characteristics previously associated with CVS, such as catheter
diameter and length. Fifth, although short-term catheters have
also been associated with CVS [28], temporary catheters were
not included in our study. This could explain the fact that, un-
like other studies investigating CVS [5], the total number of
previous catheters was not associated with SVC stenosis. The
monocentric design of this study has some advantages: (i) the
interventional radiologist reading the imaging studies and treat-
ing SVC stenosis was the same in all except one patient; (ii) all
the information is centralized in our electronic medical records;
(iii) our policy of a systematic catheter imaging study in case of
persistence of blood flow<250 mL/min guaranteed some detec-
tion uniformity, unlike in multicentric studies. However, the
limited variability of some parameters (i.e. catheter brand and
location) due to the monocentric design may have masked a po-
tential impact of these factors.
In conclusion, SVC stenosis is not a rare condition in
chronic HD patients with a TCC, but classical symptoms re-
main infrequent in the absence of a peripheral functional VA.
In patients carrying a TCC, SVC stenosis appears to be strongly
associated with diabetes and promoted by a long TCC carriage.
This highlights the need to decrease catheter use in HD (i.e. re-
duction of late referral rate, protection of veins, periodic moni-
toring of peripheral VA and availability of a multidisciplinary
VA team) and to perform an imaging study prior to AVF crea-
tion in patients with a history of central vein catheterization, es-
pecially if prolonged, as recommended by current guidelines
[29, 30]. Further large, long-term studies are warranted to con-
firm the current prevalence and risk factors of this potentially
devastating complication in HD patients.
This work was presented at the Annual Congress of
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